Please use this identifier to cite or link to this item:
Title: Section 3. A discussion of flexible dosing and patient-centered therapy: highlights of the asthma summit 2009: beyond the guidelines
Authors: Canonica, G. W.
Brightling, Christopher Edward
First Published: 15-Feb-2010
Publisher: BioMed Central
Citation: World Allergy Organization Journal, 2010, 3 (2), pp. 31-37
Abstract: Despite positive clinical experience and the published clinical benefits of monotherapy with low-or medium-dose inhaled corticosteroids or combination therapy with ICS + long-acting beta-agonist to treat asthma, many patients remain suboptimally controlled. Alternative approaches are needed, and 3 options that have had some success are: 1) using the patient's level of inflammation by established biomarkers to set treatment; 2) self-management incorporating flexible dosing; and 3) using a single inhaler for rescue and maintenance therapy. Which strategy for which patient depends ultimately on the individual patient's disease burden, life-style, comorbidities, preferences, and his or her ability to self-manage the disease, including assessing symptoms and adhering with therapy.
DOI Link: 10.1097/WOX.0b013e3181d27cd8
eISSN: 1939-4551
Version: Publisher Version
Status: Peer-reviewed
Type: Journal Article
Rights: Copyright © World Allergy Organization; licensee BioMed Central Ltd. 2010. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Appears in Collections:Published Articles, Dept. of Infection, Immunity and Inflammation

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.